MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

2,3 Efficacy findings from the KEYNOTE-868/NRG- GY018 trial (NCT03914612) led to the FDA’s approval of pembrolizumab for endometrial carcinoma. The trial stratified 222 patients to the MMR- deficient ...

MSD acquired the therapy from Acceleron Pharma. Credit: Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. MSD has received ...

Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's (MRK.N), opens new tab therapy to treat a rare lung condition, marking another ...

The National Safety Council (NSC) has released its 2023-2024 MSD Solutions Index. This latest edition reveals advancements in workplace musculoskeletal disorder (MSD) prevention while identifying ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MSD has already reported data from its pivotal NRG-GY018 study of Keytruda (pembrolizumab), which showed a similar 70% reduction in a dMMR population, but so far, there's no word on a regulatory ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial ...

RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the Phase 3 MOVe-NOW clinical trial to evaluate ...